Femasys Inc. (NASDAQ: FEMY) introduced its new fertility solution, FemaSeed Complete, on April 22, 2026. The product merges the company’s intratubal insemination (ITI) technology with its FemSperm sperm‑preparation kit, enabling OB‑GYN practices to perform first‑line insemination entirely in‑office.
The launch taps into a large U.S. infertility market that affects an estimated 10 million women, yet fewer than half receive care. By offering a convenient, cost‑effective alternative to specialized fertility centers, Femasys aims to capture a share of the $10‑plus‑billion market and broaden access to early treatment.
Femasys has been steadily expanding its reproductive‑health portfolio. The company’s earlier FemaSeed product received FDA clearance in September 2023, and its FemBloc permanent birth‑control system has secured approvals in Europe, the UK, and New Zealand while U.S. pivotal trials progress. The FemaSeed Complete launch signals a continued commitment to making fertility care more accessible and integrated into routine OB‑GYN practice.
Financially, Femasys has historically reported net losses. The fiscal year ending December 31, 2025 recorded a net loss of $18.6 million, and the Q4 2025 earnings release on March 31, 2026 reported an EPS of –$0.06, beating estimates of –$0.08. The company is also addressing Nasdaq’s minimum bid‑price requirement, with a reverse stock‑split proposal pending a shareholder vote on April 29, 2026. While the new product may drive future revenue growth, the company remains loss‑making and must maintain disciplined cost control.
CEO and founder Kathy Lee‑Sepsick said, “Current fertility care delivery is not aligned with where patients seek care, creating a significant opportunity for change. Our market research shows strong patient interest in accessing fertility care earlier and more cost‑effectively within the OB/GYN setting. Through our Femasys fertility portfolio, we are enabling physicians to perform in‑office procedures that can expand care, accelerate time to treatment, and give more women the opportunity to achieve pregnancy.”
Femasys will showcase FemaSeed Complete at the ACOG Clinical and Scientific Meeting in Washington, D.C., from May 1‑3, 2026, and plans to pursue broader commercialization in the coming months. The launch represents a significant expansion of the company’s fertility portfolio and could provide an additional revenue stream beyond its flagship FemBloc birth‑control system, while the company continues to navigate regulatory compliance and financial challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.